logo
Kennedy Claims Doctors Profit Off Vaccines. In Fact, Many Lose Money on Them.

Kennedy Claims Doctors Profit Off Vaccines. In Fact, Many Lose Money on Them.

New York Times5 days ago
Dr. Stacey Bartell wanted to offer vaccines to her patients. But at her small family medicine practice in a Detroit suburb, she could not find a way to make the finances work.
Stocking enough vaccines for her patients would cost thousands of dollars upfront, with no guarantee the sum would be recouped. She employed just one nurse practitioner, and would have to hire additional staff to manage the inventory and stay on top of insurance billing. And the special refrigerators required to store vaccines would cost another $1,000.
She knew how much vaccines mattered to her patients' health. But it was money her practice, which was already operating on thin margins, couldn't afford to spend.
'We just haven't been able to shore it up here,' Dr. Bartell said. Instead she has to send her patients to pharmacies and the county health department for their shots — a concession that 'hurts my heart,' she said.
So a few weeks ago, when Robert F. Kennedy Jr., the health and human services secretary, claimed in an interview with Tucker Carlson that vaccine profits created 'perverse incentives' for pediatricians to push immunizations, Dr. Bartell was confused.
Doctors widely consider vaccines to be a money pit. Research shows that most pediatricians either break even or lose money on shots. One 2017 study found that nearly a quarter of family medicine providers and 12 percent of pediatricians stopped purchasing vaccines because of prohibitive costs.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT

Yahoo

timean hour ago

  • Yahoo

BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT

Prime Medicine Inc. (NASDAQ:PRME) is one of the . On July 16, BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine Inc. (NASDAQ:PRME) and set a price target of $10.00. The analyst based the rating on the company's innovative gene editing technology. A scientist examining a microchip and circuit board in a hi-tech lab. Prime Medicine Inc. (NASDAQ:PRME) recently secured additional funding totaling $39 million from the Cystic Fibrosis Foundation, which, according to the analyst, highlights the potential of its prime editing platform and preclinical data in cystic fibrosis. Biliouris reasoned that the company's notable 90% editing efficiency attained in the second patient treated ex vivo, when coupled with this financial backlog, reduces the risk of Prime Medicine Inc.'s (NASDAQ:PRME) platform and increases its credibility. Headquartered in Cambridge, MA, Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that develops one-time curative genetic therapies. While we acknowledge the potential of PRME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT

Yahoo

timean hour ago

  • Yahoo

BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT

Prime Medicine Inc. (NASDAQ:PRME) is one of the . On July 16, BMO Capital analyst Kostas Biliouris maintained a Buy rating on Prime Medicine Inc. (NASDAQ:PRME) and set a price target of $10.00. The analyst based the rating on the company's innovative gene editing technology. A scientist examining a microchip and circuit board in a hi-tech lab. Prime Medicine Inc. (NASDAQ:PRME) recently secured additional funding totaling $39 million from the Cystic Fibrosis Foundation, which, according to the analyst, highlights the potential of its prime editing platform and preclinical data in cystic fibrosis. Biliouris reasoned that the company's notable 90% editing efficiency attained in the second patient treated ex vivo, when coupled with this financial backlog, reduces the risk of Prime Medicine Inc.'s (NASDAQ:PRME) platform and increases its credibility. Headquartered in Cambridge, MA, Prime Medicine Inc. (NASDAQ:PRME) is a biotechnology company that develops one-time curative genetic therapies. While we acknowledge the potential of PRME as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Your Guide To Navigating Perimenopause In Your 30s And Beyond
Your Guide To Navigating Perimenopause In Your 30s And Beyond

Yahoo

time2 hours ago

  • Yahoo

Your Guide To Navigating Perimenopause In Your 30s And Beyond

The first time I heard the word "perimenopause," I felt like I had been late to a party I wasn't invited to. Don't get me wrong—it's not a party I'm dying to go to, but I couldn't believe how little I knew about such a pivotal reproductive life stage. And I'm not alone. When I set out to report on this often overlooked and misunderstood phase of life, nearly a dozen women I spoke to initially had zero clue that perimenopause could be the root of their sudden and varied symptoms. They also had no idea it can last anywhere from two to 10 years (sometimes more), it's characterized by a fluctuation of hormones (not necessarily a sharp decline), and, perhaps most significantly, it can start as early as your mid-thirties (I couldn't believe it either). The good news is there's more awareness than ever around perimenopause, thanks to a growing call for menopause education, millennials' track record of breaking taboos, and a little thing called the social media algorithm. And we hope this series of stories, below, contributes to that. You'll find a special report on millennials and perimenopause, real stories from women on how they successfully manage their peri symptoms, hormonal and non-hormonal treatment options, where to actually find good care, tips on how to stay healthy in peri and beyond, and how to advocate for menopause policy in your state. Our grandmothers and mothers may not have had the word to describe this phase of life, but we do. And the more prepared we are for it, the better (and healthier) we are. Read the stories, share them with your friends, and let us know what you think in the comments—this is only the beginning of the conversation. Read The StoriesMillennials Are Entering The Perimenopause Chat READ THE STORYYour Brain (And Heart) On Hot Flashes READ THE STORYHow Young Is Too Young For Hormone Therapy? READ THE STORYHow These Women Are Successfully Managing Their Perimenopause Symptoms READ THE STORYWhere To Actually Find Good Perimenopause Care READ THE STORYHow To Stay Healthy In Perimenopause And Beyond READ THE STORYWe Need To Fight For Menopause Policy Now More Than Ever READ THE STORY This story appears in the Summer 2025 issue of Women's By Heami LeeProp Styling By Christine Keely You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store